Dr. Jeanny B Aragon-Ching, MD, F.A.C.P.

Claim this profile

Inova Health Care Services

Studies Bladder Cancer
Studies Transitional Cell Carcinoma
2 reported clinical trials
5 drugs studied

Area of expertise

1

Bladder Cancer

Jeanny B Aragon-Ching, MD, F.A.C.P. has run 2 trials for Bladder Cancer. Some of their research focus areas include:

HER2 positive
Stage III
Stage IV
2

Transitional Cell Carcinoma

Jeanny B Aragon-Ching, MD, F.A.C.P. has run 2 trials for Transitional Cell Carcinoma. Some of their research focus areas include:

HER2 positive
Stage III
Stage IV

Affiliated Hospitals

Image of trial facility.

Inova Health Care Services

Image of trial facility.

Inova Schar Cancer Institute

Clinical Trials Jeanny B Aragon-Ching, MD, F.A.C.P. is currently running

Image of trial facility.

Disitamab Vedotin + Pembrolizumab vs Chemotherapy

for Bladder Cancer

This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.

Recruiting

2 awards

Phase 3

Image of trial facility.

Disitamab Vedotin + Pembrolizumab

for Bladder Cancer

This trial is testing a new drug called disitamab vedotin, alone or with pembrolizumab, for patients with advanced or metastatic HER2 expressing bladder cancer. Disitamab vedotin is designed to target HER2 and has been approved for other types of cancer. The study aims to see if these drugs can effectively treat the cancer and what side effects they might cause.

Recruiting

1 award

Phase 2

4 criteria

More about Jeanny B Aragon-Ching, MD, F.A.C.P.

Clinical Trial Related

2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Jeanny B Aragon-Ching, MD, F.A.C.P. has experience with

  • Disitamab Vedotin
  • Pembrolizumab
  • Carboplatin
  • Cisplatin
  • Gemcitabine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jeanny B Aragon-Ching, MD, F.A.C.P. specialize in?

Is Jeanny B Aragon-Ching, MD, F.A.C.P. currently recruiting for clinical trials?

Are there any treatments that Jeanny B Aragon-Ching, MD, F.A.C.P. has studied deeply?

What is the best way to schedule an appointment with Jeanny B Aragon-Ching, MD, F.A.C.P.?

What is the office address of Jeanny B Aragon-Ching, MD, F.A.C.P.?

Is there any support for travel costs?